Schizophrenia: Redox Regulation and Volume Neurotransmission

I. Bókkon1,* and I. Antal2

1Doctoral School of Pharmaceutical and Pharmacological Sciences, Semmelweis University, Budapest, Hungary; 2Department of Pharmaceutics, Semmelweis University, Budapest, Hungary

Abstract: Here, we show that volume neurotransmission and the redox property of dopamine, as well as redox-regulated processes at glutamate receptors, can contribute significantly to our understanding of schizophrenia. Namely, volume neurotransmission may play a key role in the development of dysconnectivity between brain regions in schizophrenic patients, which can cause abnormal modulation of NMDA-dependent synaptic plasticity and produce local paroxysms in deafferented neural areas. During synaptic transmission, neuroredox regulations have fundamental functions, which involve the excellent antioxidant properties and nonsynaptic neurotransmission of dopamine. It is possible that the effect of redox-linked volume neurotransmission (diffusion) of dopamine is not as exact as communication by the classical synaptic mechanism, so approaching the study of complex schizophrenic mechanisms from this perspective may be beneficial. However, knowledge of redox signal processes, including the sources and molecular targets of reactive species, is essential for understanding the physiological and pathophysiological signal pathways in cells and the brain, as well as for pharmacological design of various types of new drugs.

Keywords: Volume neurotransmission, redox regulations, dopamine, glutamate receptors.

INTRODUCTION

Converging evidence for the neurodevelopmental theory of schizophrenia suggests that a disturbance of brain development, involving genetic and environmental factors, during the intrauterine period and the first few years after birth underlies the later appearance of psychosis during adulthood [1]. However, the pathophysiology of schizophrenia is very complex and involves several cortical and subcortical systems. Brain imaging methods such as fMRI and PET have shown that differences linked to the neurocognitive deficits in schizophrenia most commonly occur in the frontal lobes, temporal lobes and hippocampus [2]. There have also been findings of differences in the structures and sizes of definite brain areas in schizophrenia.

The dopamine hypothesis of schizophrenia has been the major neurochemical assumption for over 40 years. This hypothesis is based on two fundamental observations: dopamine-enhancing drugs can produce psychosis, and blockade of D2 dopamine receptors is the sole property common to all antipsychotic drugs [3]. The dopamine hypothesis of schizophrenia proposes that excess activation of D2 receptors is the cause of the positive symptoms (delusions, hallucinations, and thought disorder) in schizophrenia. However, antipsychotic drugs that block dopamine D2 receptors are highly effective in treating the psychosis, but have limited effects on the negative symptoms (deficits in social abilities and speech, affective flattening).

Another hypothesis concerning the cause of schizophrenia postulates a deficit of glutamate functioning [4, 5]. Usually, it focuses on the glutamate neurotransmitter and the abnormally low level of the NMDA glutamate receptor in schizophrenia based on postmortem brains of people previously diagnosed with schizophrenia. The glutamate hypothesis is also supported by the fact that glutamate-blocking drugs such as ketamine and phencyclidine imitate the psychotic symptoms of schizophrenia.

Schizophrenia is also characterized by deficits of serotonin (5-HT) [6, 7] and norepinephrine [8]. Functional interactions between the central serotonin and dopamine (DA) systems have been well documented [9]. Alterations in the brain serotonin-dopamine balance are implicated in the etiology of schizophrenia. Numerous studies have shown that 5-HT receptors can modulate dopaminergic functions. However, the modulating effect of serotonin on striatal dopamine release is controversial. For instance, serotonin could inhibit [10, 11] or stimulate DA release in the striatum [12, 13]. The serotonin hypothesis is also supported by the known hallucinogenic effect of 5-HT receptor agonists, such as lysergic acid diethylamide (LSD), hallucinogenic derivatives of phenethylamine and tryptamine [14].

The hypofunction of subsets of GABAergic interneurons in the prefrontal cortex and the hippocampus was also suggested in schizophrenia [15]. The cholinergic system includes two families of receptors (muscarnic cholinergic and the nicotinic cholinergic receptors) that use acetylcholine as a neurotransmitter. Pharmacology, neuroimaging, and postmortem studies suggest alterations in the muscarinic cholinergic system in schizophrenia [16].

Mitochondrial dysfunction has also been proposed as a cause of schizophrenia, including dysfunction of the oxidative phosphorylation mechanisms, mitochondrial hypoplasia, and altered mitochondria-related gene expression [17]. There is also some evidence of irregular cellular metabolism and
However, there is accumulating evidence for the presence of dysregulated redox processes in the prefrontal cortex in schizophrenia, involving increased glucose demand and/or cellular hypoxia.

In addition, convergent evidence has implicated developmental dysregulation of glutathione (GSH) synthesis in the pathogenesis of schizophrenia [18-20]. Lack of regulation of glutathione (GSH) synthesis in the developmental dysregulation of glutathione (GSH) synthesis in the prefrontal cortex in schizophrenia, involving increased glucose demand and/or cellular hypoxia.

Since Santiago Ramón y Cajal discovered gaps between neurons [22], neurotransmission has been considered to be a point-to-point synaptic connection. However, Paton and Vizi [23] and Knoll and Vizi [24] provided the first data indicating that neurons can communicate with each other without synapses. Vizi also provided evidence that this nonsynaptic neurotransmission (volume neurotransmission, paracrine transmission, diffusion neurotransmission) exists not only in the periphery but also in the brain [25, 26]. In the past few decades, several experiments have confirmed that neurotransmitters can be released from both synaptic and nonsynaptic sites. Thus, the extracellular space acts as an essential analog communication pathway in the brain. Volume transmissions have fundamental regulating roles in both presynaptic and postsynaptic processes.

The vast majority of monoaminergic varicosities create nonsynaptic contact that permit the release of transmitters directly into the extrasynaptic areas. It is estimated that about 95% of catecholamine (the most abundant catecholamines are dopamine, norepinephrine, and epinephrine) terminals are nonsynaptic and that each neuron is positioned within less than 30 μm of a norepinephrine bouton in the brain [27].

**REACTIVE SPECIES AS FUNDAMENTAL CELLULAR SIGNALS**

Thus far, reactive oxygen species (ROS) - hydrogen peroxide (H$_2$O$_2$), superoxide anion (O$_2^-$), hydroxyl radical (HO), and singlet oxygen (‘O$_2$) - and reactive nitrogen species (RNS) - nitric oxide (NO) and peroxynitrite anion
(ONOO·) have been considered as very harmful agents that cause damage to macromolecules through nucleophilic attack [28]. These reactive species are generated primarily by the mitochondrial respiratory chain, NADPH oxidases, cyclooxygenases, lipoxygenases, cytochrome P450 oxidases, xanthine oxidase, nitric oxide synthase (NOS), etc. [29]. The harmful effects of reactive species are collectively termed oxidative stress and occur in biological systems when there is overproduction of ROS/RNS and/or a deficiency of enzymatic and non-enzymatic antioxidants [30, 31].

However, emerging evidence indicates that reactive species are essential signaling molecules for cells. Recent findings have shown that diverse kinds of reactive species and several products derived from their reactions, such as oxidized lipids and proteins, are necessary for regulating biological functions at all levels of biological organization [29, 32]. Reactive species and their derivatives stimulate distinct signaling pathways that can interact with each other. It may be paradoxical that diverse ROS-mediated processes protect cells against ROS-induced oxidative stress and restore redox homeostasis. During physiological (pathophysiological) processes, ROS and RNS can act as secondary messengers and control gene expression, apoptosis, cell growth, cell cycle, cell adhesion, chemotaxis, protein-protein interactions and enzymatic functions, Ca²⁺ and redox homeostasis, etc., in cells [29, 32-38].

**REACTIVE SPECIES AS FUNDAMENTAL SIGNALS IN THE BRAIN**

During neuronal activity, a considerable volume of oxygen is used to maintain neuronal membrane potentials, which accordingly generate ROS and RNS. Various ROS and RNS as well as their derivatives act as signaling molecules in cerebral circulation and are required for signal processes such as synaptic plasticity and memory formation [39-41]. Reactive species control uptake of the excitatory neurotransmitter glutamate mainly by oxidation of protein sulfhydryl groups in rat cortical astrocytes [42].

The NO (nitric oxide) free radical molecule can freely cross cell membranes, acting as a neurotransmitter, neuromodulator, and messenger. Neuronal NO modulates synaptic activity by regulating neurotransmitter release and takes part in processes involved in synaptic plasticity, such as long-term potentiation, depression and synaptic genesis [43-46]. NO, as a diffusible messenger, increases glutamate release in NMDA receptor activation processes [47].

NADPH oxidases (nicotinamide adenine dinucleotide phosphate-oxidase) and other sources of superoxide are required for the hippocampal long-term potentiation (LTP) and hippocampus-dependent memory [48-51].

The NMDA subtype of glutamate receptors consists of a complex of various subunits. Since numerous cysteine residues are located in NMDA receptor subunits, which are redox-regulable, ROS and NO have important mediators of NMDA receptor signaling processes. During NMDA receptor activation, NADPH oxidase generates ROS via signaling pathway involving NO, cyclic guanosine monophosphate (cGMP), and protein kinase G (GPKG) [52].

Hydrogen peroxide (H₂O₂) is emerging as a ubiquitous messenger in various cells and the brain. Oxidative deamination of monoamines by mitochondrial MAO is accompanied by the reduction of molecular oxygen to H₂O₂. Recently, Bao et al., [53] demonstrated that respiring mitochondria are the primary source of H₂O₂ generation for dynamic neuronal signaling.

In brief, many experiments have provided evidence that reactive species act as essential signals during physiological (pathophysiological) processes in cells and the brain.

**MITOCHONDRIAL NETWORKS AS REDOX CENTERS AND METABOLIC HUBS**

To date, usually, mitochondria are considered as simple cellular energy sources in most scientific literatures. However, there is accumulating evidence that mitochondria function as essential centres for cellular signaling pathways in cells. According to Aon et al., [54, 55] mitochondria can function as metabolic hubs that produce ROS signaling molecules with scale-free dynamics. Namely, the coordination between mitochondria within the network appears to be ROS mediated. Mitochondria are poised at the convergence of most anabolic and catabolic pathways through the tricarboxylic acid cycle. Thus, mitochondria can act as metabolic and redox hubs due to their numerous links to other pathways as inputs (sources) or outputs (sinks). In addition, growing evidence demonstrates that shapes and spatiotemporal arrangements of mitochondria can be very different in different cell types [56]. Moreover, activity-dependent mitochondrial redistribution takes place in neurons [57].

Mitochondria are essential determinant of the excitability and viability of neurons. Mitochondria take up about 25% of the cell volume in neurons and play fundamental roles in cellular redox and Ca²⁺ homeostasis, ATP generation, free radical production, regulation of neurotransmitter release, cell growth, apoptosis, cell signaling, iron metabolism, steroidogenesis, and many other functions [40, 58].

In contrast to the textbook description of mitochondria as small spherical organelles in cells, mitochondria in muscular, neuronal and connective tissue are principally filamentous [56, 59, 60]. Mitochondria are functionally connected, i.e., they produce a dynamic network within neuronal cells. Mitochondria continuously fuse and divide, and their morphology and intracellular distribution change according to the energy demands of cells [61, 62]. Because mitochondria are key players in cellular redox homeostasis and signaling and one of the main sources of free radicals, they play a central role in redox-dependent post-translational reversible oxidative modifications of proteins such as tyrosine phosphatases and protein tyrosine kinases.

Mitochondria also participate in the synthesis and secretion of neurotransmitters. Some essential steps in the metabolism of the major excitatory neurotransmitter glutamate and the principal inhibitory neurotransmitter GABA (gamma-aminobutyric acid) take place in the mitochondrial tricarboxylic acid cycle [63].
Besides, mitochondrial monoamine oxidase (MAO) enzyme performs a key metabolic role in the turnover of serotonin, dopamine, norepinephrine, and epinephrine in the brain [64-66]. Oxidative deamination of monoamines by mitochondrial MAOs is accompanied by the reduction of molecular oxygen to H₂O₂. Namely, reactive species are generated by mitochondrial monoamine oxidases during natural metabolism of serotonin, norepinephrine, epinephrine, and dopamine. Because oxidative deamination of monoamines by mitochondrial MAOs is a regulated process, reactive species generated during oxidative deaminations may also serve as essential signaling molecules in cells.

In contrast, excess (unregulated) production of dopamine (monoamines) can induce overproduction of H₂O₂ and superoxides via monoamine oxidases, as well as leading to an excess of auto-oxidized dopamine that can cause lipid peroxidation and DNA and protein modifications and interact with the mitochondrial electron transport system. Dopamine can inhibit brain mitochondrial respiration that involves generation of reactive oxygen species [67]. In addition, dopamine-associated inhibition of mitochondrial respiration is dependent on MAO and H₂O₂ [68].

**DOPAMINE AND SEROTONIN CAN REVERSIBLY REGULATE MITOCHONDRIAL MOTILITY AND DISTRIBUTION**

Recently, it was demonstrated that the neurotransmitter dopamine and serotonin (5-HT) can reversibly regulate mitochondrial motility and distribution in cultured hippocampal neurons [69, 70]. Chen et al., found that dopamine bears a net inhibitory effect on mitochondrial movement. In contrast, 5-HT performed a stimulatory effect on mitochondrial movement. Chen et al. suggested that dopamine and 5-HT can determine the distribution of mitochondria as energy sources in neurons.

However, because mitochondria can function as metabolic and redox hubs, the distribution of mitochondria represents a distribution not only of energy sources but also of metabolic and redox processes. In other words, when dopamine and 5-HT determine the distribution of mitochondria in neurons, they also determine cellular redox and Ca²⁺ patterns, ATP generation patterns, free radical patterns, spatiotemporal patterns of various cell signals, neuronal membrane potentials, and many other parameters. It is very possible that other neurotransmitters, such as norepinephrine and acetylcholine, can also affect mitochondrial movement and distribution.

**CATECHOLAMINES AND SEROTONIN AS ANTIOXIDANTS**

Catecholamines and serotonin and their metabolic products can be either neurotoxic or neuroprotective. However, catecholamines and serotonin bear free radical scavenging and neuroprotective abilities [71-74]. At high doses, catecholamines induce apoptosis but prevent free radical-mediated neurotoxicity as antioxidants without being coupled to the receptors [74]. The catechol structure is a fundamental component for the antioxidative effect of catecholamines. The redox state of the cell is largely linked to the iron (and copper) redox couple and is maintained within strict physiological limits. Catecholamines can inhibit generation of free radicals by chelating various metals; i.e., they can balance redox potential by complex formation [75, 76].

Serotonin and its precursor have great antioxidant properties in the brain [73]. Serotonin attenuates free radical-induced neuronal death without being coupled to serotonin receptors in cultured mouse cortical neurons [77]. Norepinephrine reduces caspase activation and ROS production in cholinergic neurons [78].

Dopamine and its five receptor subtypes play various roles in the central nervous system. Dopamine exerts its actions through two families of cell surface receptors that belong to the class of G protein-coupled receptors. D1-like receptors (D1, D5) stimulate adenylyl cyclases, while D2-like receptors (D2, D3, D4) inhibit adenylyl cyclases [79]. Activation of D1 and D5 receptors produces antioxidant responses [80, 81]. Antioxidant response to the D5 induction is mediated by inhibition of NAPDH oxidase activity [80]. Besides, dopamine has concentration-dependent effects on ROS production. It acts as an antioxidant at physiological concentrations, but as a prooxidant at higher concentrations. The neuroprotective outcomes of dopamine can be both receptor-mediated and non-receptor-mediated [82]. However, dopamine is a potent antioxidant, and when it reduces reactive oxygen species, it is converted into neurotoxic dopamine quinones. Dopamine quinone can rapidly recover to dopamine by an ambient antioxidant such as glutathione or ascorbate. In the absence of ambient antioxidants, quinones form neurotoxic o-semiquinones, which are free radicals [83].

Because mitochondria play key roles in the synthesis and secretion of classical neurotransmitters and that catecholamines and serotonin can act as antioxidants and free radical scavengers, mitochondria can also control redox processes via the regulation of neurotransmitter metabolism and secretion.

**GLUTATHIONE IN SCHIZOPHRENIA**

The cellular thiol redox state is a fundamental mediator of numerous signaling, metabolic, and transcriptional processes in cells. The glutathione (GSH) and thioredoxin (TRX) systems are the two key and ubiquitously expressed antioxidant systems that reduce thiol (-SH) groups [84]. The GSH and TRX systems maintain a reduced intracellular redox condition in cells by the reduction of protein thiol groups. Namely, they keep signaling components in a reduced state and are counterbalanced in signaling by oxidative mechanisms. GSH (γ-glutamyl-cysteine-glycine, a tripeptide that exists in reduced monomeric (GSH) and oxidized dimeric forms (GSSG)) is the major thiol antioxidant and redox buffer in cells and is abundant in the cytosol, nuclei, and mitochondria.

There is increasing evidence that the glutathione metabolism is abnormal in schizophrenia and that a weakened capacity to synthesize GSH under oxidative stress is a susceptibility factor for schizophrenia. Namely, patients with schizophrenia indicate a deficit in glutathione levels in the prefrontal cortex and cerebrospinal fluid, as well as the re-
duction of gene expression of GSH-synthesizing enzymes [18, 19, 85]. However, glutathione can act as a neuromodulator at the glutamate receptors and as a neurotransmitter at its own receptors. GSH plays a major role in modulating redox-sensitive sites, including NMDA receptors [86]. In slices of rat hippocampus, reduced GSH levels weaken NMDA-mediated responses and synaptic plasticity [20].

Cabungcal et al. [87] provide experimental evidence that glutathione deficit, during postnatal development, induces dysfunctions in GABAergic neurons in anterior cingulate cortex of rats. These dysfunctions of GABAergic interneuron can have wide-ranging effects on the neuronal circuitry of prefrontal cortex and its output to additional brain areas.

REDOX REGULATION AT IONOTROPIC NMDA RECEPTORS

Glutamate activates two types of glutamate receptors: ionotropic (iGluRs) and metabotropic glutamate receptors (mGluRs) [88]. Ionotropic glutamate receptors have been subdivided into \( \alpha \)-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), kainite, and \( N \)-methyl-D-aspartate (NMDA) receptor subclasses.

It is accepted that the glutamate ionotropic NMDA receptor is the principal molecular structure for controlling synaptic plasticity and memory function. NMDAR activation starts several events, including calcium influx, activation of nitric oxide synthase, and superoxide formation [89, 90]. Earlier studies have suggested that mitochondria are a principal source of NMDA-induced superoxide production. However, recent experiments have indicated that NADPH oxidase can be the main source of superoxide production following neuronal NMDAR activation [91]. It is probable that initial superoxide signals produced by NADPH oxidase can stimulate secondary mitochondrial superoxide production.

Redox modulation has been recognized as an essential system in the regulation of the NMDA receptor [86]. Oxidizing agents decrease, but reducing agents enhance NMDA-evoked currents. Numerous cysteine residues are located in NMDA receptor subunits, which are redox-regulable.

It is possible that redox agents can produce conformational changes in the NMDAR protein at cysteine residues to promote or inhibit the development of disulfide bridges, which induce changes in channel properties [92]. The NMDA receptor can also be regulated by nitric oxide (NO)-related species (not involving cyclic GMP) and endogenous glutathione [86].

During excitation of a neuron by glutamate, nitric oxide is produced that stimulates exocytosis and release of dopamine and glutamate from nearby neurons [93]. Thus, dopamine can alter the strength of glutamatergic synapses and affect synaptic plasticity. It is possible that nonsynaptic volume transmission of dopamine (as a form of spatiotemporal signaling) complements classic synaptic transmission and organizes local activity among neuron groups.

Smythies has presented research about the redox biochemical basis of learning and neurocomputation [94-97]. His theory is based on redox mechanisms at the glutamate synapse. He emphasized that catecholamines are potent antioxidants and free radical scavengers. According to Smythies [94], “…it is possible that catecholamines from the en passage DA bouton (and possibly norepinephrine (NE) boutons in NE systems) may modulate the redox status of the adjacent glutamatergic synapse by scavenging ROS”. However, Smythies was the first who emphasized that synaptic and nonsynaptic (volume transmission) transmission processes can be redox-based mechanisms.

IONOTROPIC AMPA GLUTAMATE RECEPTORS AND REGULATION OF STRIATAL DOPAMINE RELEASE BY DIFFUSIBLE H\(_2\)O\(_2\)

AMPA (\( \alpha \)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) ionotropic glutamate receptors are expressed in every part of the mammalian brain and are composed of various combinations of glutamate receptor subunits (GluR1–GluR4) [98, 99]. Glutamate receptor subclasses can coexist in the same cell [100]. Subunits and splice variants of AMPA receptors also differ by brain region.

Regulation of dopamine-dependent glutamate transmission is relatively known. For instance, glutamate release can be inhibited by D2 dopamine receptors on corticostriatal afferents [101]. This dopamine regulation is achieved by nonsynaptic volume neurotransmission [102].

In contrast, how synthetically released glutamate control dopamine release in striatum is less understandable. However, the effect of ionotropic glutamate-receptor activation on dopamine release should be indirect because AMPA receptors are not expressed on DA terminals [103, 104]. Several experiments support that \( H_2O_2 \) can function as a signaling messenger in the brain and other tissues by various \( H_2O_2 \) regulable processes such as kinases, phosphatases, transcription factors, ion channels, etc. [32, 105-107].

Recently, Avshalumov et al. [108] reported that activation of ionotropic AMPAR produce diffusible \( H_2O_2 \), which opens ATP-sensitive potassium (\( K_{ATP} \)) channels and thereby inhibits synaptic dopamine release in striatum (the major input station of the basal ganglia system). In other words, the mechanism by which \( H_2O_2 \) can inhibit dopamine release is activation of ATP-sensitive potassium channels.

The major subcellular sources of \( H_2O_2 \) production are mitochondrial respiration, monoamine oxidase (MAO), and NADPH oxidase. Very freshly, Bao et al. [53] demonstrated that fast \( H_2O_2 \) production is due to the mitochondrial respiration during glutamatergic activation of AMPA receptors in the striatum. Namely, respiring mitochondria are the major sources of \( H_2O_2 \) generation for fast, dynamic neuronal signaling. In contrast, MAO and NADPH oxidase do not contribute to dynamic, fast (subsecond) \( H_2O_2 \) signaling in the striatum, nevertheless these act as \( H_2O_2 \) sources at longer time scales.

REDOX-CONTROLLED PHOSPHORYLATION OF NMDAR SUBUNITS

The phosphorylation of NMDAR subunits by protein kinases plays a critical role in NMDAR regulation and syn-
aptic plasticity [109, 110]. For instance, NMDAR currents can be enhanced by increasing tyrosine kinase activity [110].

Numerous studies have demonstrated that reversible oxidative modifications (reversible thiol modification) of protein tyrosine kinases and protein tyrosine phosphatas by ROS play essential roles in regulating their enzymatic activity [111-113]. Although these oxidative modifications are reversible, their effects on the enzymatic activity of tyrosine phosphatas and tyrosine kinases can be even opposite. Thus, protein tyrosine phosphorylation-based signaling pathways are under the regulation of reactive oxygen species.

Li et al., suggested, [114] that an impairment in NR1 subunit phosphorylation of NMDA receptors produces glutamergic hypofunction that can contribute to behavioral deficits related to psychiatric disorders. However, these findings indicate that phosphorylation of NMDAR subunits by protein kinases is also subject to regulation by redox and free radicals.

METABOTROPIC GLUTAMATE RECEPTORS

The metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors with seven transmembrane domains that can modulate brain excitability via presynaptic, postsynaptic and glial mechanisms. To date, the existence of eight metabotropic glutamate receptors (from mGlu1 to mGlu8) have been identified, and these receptors have been clustered into three groups (I-III). mGluRs are not ion channels but are active through an indirect metabotropic process [115]. mGluRs modulate the activity of ligand- and voltage-gated ion channels by means of G-protein-mediated activation of such intracellular messenger cascades as phospholipase C, adenyl cyclase and protein kinase C.

In contrast to the glutamate ionotropic receptors, such as NMDA, AMPA and kainate receptors, which are responsible for fast excitatory transmission, mGluRs play modulatory roles in glutamatergic synaptic transmission by modulating the ion channel activity and neurotransmitter release. mGlu receptors can regulate neuronal function separately from the ionotropic NMDA receptors (iGluRs) and protect against cellular injury by regulating oxidative and redox processes. For instance, glutamate can induce dopamine efflux by metabotropic GluR1 activation.

However, mGluR agonists can modulate - increase or decrease - the release of dopamine in the striatum and nucleus accumbens [116-118]. One possible explanation for this contradiction is that mGluR subtypes differently modulate the release of extracellular dopamine in different areas of the brain [117]. It was suggested that mGluRs can regulate neuronal injury and survival, likely via protein kinases and cysteine protease signaling pathways that affect mitochondrial controlled programmed cell death [119].

However, since mGluRs can modulate the release of dopamine (dopamine can acts as an antioxidant at physiological concentrations and modulate the redox status of the adjacent glutamatergic synapse), and act via protein kinases and cysteine protease (ROS play essential roles in regulating their enzymatic activity) signaling pathways that affect mitochondrial processes (mitochondrial networks are the main sources of ROS), indicating that mGluR associated signal pathways are also redox-linked processes.

MODULATION OF NMDA RECEPTORS AND DOPAMINE TRANSPORTERS BY ZINC

Functional native NMDAR, which is a heteromultimer of NR1 and NR2 subunits [120, 121], play multifaceted roles in synaptic plasticity. Zinc can act via these receptors to modulate bidirectional plasticity. The existence of zinc in synaptic terminals and its extracellular release during synaptic transmission [122, 123] suggest that zinc is a significant modulator of synaptic plasticity. For instance, zinc can modulate synaptic plasticity in hippocampal CA1 region by different mechanisms that are dependent on zinc concentrations [124].

The dopamine transporter (DAT) is a specific membrane protein in dopaminergic neurons. Dopamine reuptake by DAT regulates the extracellular dopamine concentration in brain areas with dopaminergic innervation. Lately, Pifl et al. [125] demonstrated the first evidence that DAT regulation by Zn2+ is intensely modulated by the membrane potential and chloride. In other words, the direction (inhibitory or stimulatory) of the Zn2+ effect on dopamine reuptake depends on the membrane potential and chloride distribution of cells.

Intra- and extracellular redox states are closely linked to various ions. During synaptic transmission, release of zinc ions into extracellular space serves an important modulatory role in plasticity. The catechol structure is an essential component for the antioxidative effect of dopamine. However, dopamine may also play a functional role in the regulation of zinc ions by chelating them, which can in turn have an indirect modulatory effect on NMDAR function and a modulatory effect on dopamine reuptake. In fact, some studies indicate that extracellular zinc chelators modulate NMDAR in the CA3 region [126].

REDOX-RELATED EPIGENETICS IN SCHIZOPHRENIA

Recent works indicate that an epigenetic mechanism is also an attractive hypothesis for a molecular contribution to schizophrenia. Accumulating evidence shows that schizophrenia may arise from the abnormal epigenetic regulation of multiple genes. CpG islands (made up of CpG dinucleotides clustered together) play a critical role in controlling gene expression within the promoters of specific genes. Cytosine methylation (i.e., formation of 5-methylcytosine, catalyzed by a DNA cytosine-5 methyltransferase (DNMT)) is found essentially at CpG dinucleotides in animals [127, 128]. In general, the epigenetic silencing of gene expression is related to the hypermethylation of CpG islands. It has been suggested that abnormal gene expression (for instance, of the reelin, glutamic acid decarboxylase, and NMDA receptor genes) in GABAergic neurons is a consequence of promoter hypermethylation mediated by the overexpression of DNA methyltransferase in schizophrenic patients [129-131].

However, production of oxygen, free radicals and glutathione (GSH) influences gene expression and chromatin structure [132]. GSH is the key thiol antioxidant and redox buffer in cells and is present in high concentrations (in
millimolar concentrations) in the cytosol, nuclei, and mito-
chondria [133]. When GSH production increases, it affects
DNA and histone methylation by limiting the availability of
S-adenosylmethionine (a general co-substrate involved in
methyl group transfers), which is a cofactor utilized during
epigeneic control of gene expression by DNA and histone
methyltransferases. Although a great number of experiments
have provided evidence that reactive species act as funda-
mental signals during physiological (pathophysiologial)
processes in cells and the brain, stressful events can produce
redox imbalances and unregulated free radical production in
neurons, which cause DNA injury and can influence gene
expression by affecting DNA (and histone) methylation. In
addition, excess free radical production perturbs the GSH
antioxidant and redox buffer system. In brief, redox control
also plays an essential role in epigenetic mechanisms of
schizophrenia.

**REDOX REGULATION AND NEUROLEPTIC
COMPOUNDS**

Neuroleptics are antipsychotic compounds used in the
treatment of mental illnesses. Both first-generation antipsy-
chotics (also called conventional or typical antipsychotics,
classified according to their chemical structure, (for instance,
chlorpromazine, haloperidol, perphenazine, etc.) and second-
generation antipsychotics (also called atypical antipsychot-
classified according to their pharmacological properties,
for instance, risperidone, quetiapine, clozapine, olanzapine,
etc.) are principally dopamine antagonists that are effective
in treating the positive symptoms of psychosis. More recent
research is questioning the view that second generation anti-
sychotics are superior to first generation typical antipsy-
chotics [134]. However, there is the lack of effectiveness
of typical and atypical antipsychotic drugs on cognitive
and emotional impairments in schizophrenia [135-137].
Recently, there is an evolving picture about schizophrenia
moving from dopamine to glutamatergic-centered hypothesis
[138, 139].

However, because various antipsychotics exert diverse
effects on neurotransmitter processes, and many neurotrans-
mitters (catecholamines and serotonin) have direct free radi-
cal scavenging property, and redox modulation is an essen-
tial system in the regulation of the NMDA receptors, it
means that antipsychotics basically effects on redox-linked
neurotransmitter communication.

In addition, antipsychotics have not only therapeutic
benefits, but they also produce significant side effects such
as weight gain, lowered life expectancy, agranulocytosis
(lowered white blood cell count that includes neutrophils,
basophils, and eosinophils), tardive dyskinesia (repetitive,
 involuntary movements, such as grimacing, tongue protru-
sion, lip smacking, rapid eye blinking, etc.), diabetes[140-142]. Neuroleptics can alter the blood-brain barrier
and increase iron transport into the brain from peripheral
stores [143, 144], which can be linked to the extrapyramidal
motor side effects and to the pathophysiology of tardive
dyskinesia. However, dopaminergic function is dependent
on redox-active iron metabolism [143]. The increase of
redox-active iron levels in the brain may cause cognitive
impairment.

Side effects of antipsychotics are also linked to the
impairment of normal mitochondrial processes (functional
and ultrastructural mitochondrial malfunctions) [145, 146].
Recently, Casademont et al. [147] concluded that both
typical and atypical antipsychotics inhibit the mitochondrial
electron transport chain. For instance, antipsychotic valproic
acid induces homocysteine elevation (elevation of
homocysteine (a thiol-containing amino acid that is formed
when methionine is converted to cysteine) in the plasma is
 correlated with complex diseases, including cardiovascular
and neurodegenerative diseases) that influences the redox
homeostasis and can contribute to neuronal degeneration
and mitochondrial dysfunctions due to its excitotoxic (chronic
dysregulation of the intracellular Ca^{2+} homeostasis) proper-
ties [148, 149]. Homocysteine decreases intracellular glut-
athione peroxidase activity and alters mitochondrial gene
expression, structure, and function [150].

However, mitochondria are key determinants of the ex-
citability and viability of neurons and operate as metabolic
and redox hubs. In brief, both useful and harmful side effects
of antipsychotics are also linked to the redox-dependent neu-
rotransmitter and redox-dependent neurobiochemical proc-
esses.

**SUMMARY AND CONCLUSIONS: LOCAL PAROXYSM
AND REDOX PROCESSES IN SCHIZOPHRENIA**

Burke suggested [151] that schizophrenic visual halluci-
nations may be due to deafferentation and dysintegration
de finite visual structures that induce an increase in the
excitability of deafferented neurons. This deafferentation
is associated with an increase in spontaneous activity
and synchronization of nerve discharges. Thus, hallucination
may be considered as a local paroxysm in some visual
structures.

Stressful events can lead to redox imbalances and in-
flammatory processes in the brain. This atypical redox regu-
lation induces anomalies, including mitochondrial dysfunc-
tions. Although gene expression changes are usually attrib-
uted to mutations, epigenetic processes also play an essential
role in controlling gene expression. Thus, stressful incidents
produce metabolic defects that affect epigenetic enzymes and
cause uncontrolled overproduction of reactive species that
alter DNA methylation and histone modifications. Finally,
stressful-driven processes can lead to the regression of syn-
apses and deafferentation of the brain circuits during neuro-
development. This regression entails the loss of synaptic
spines, which is under the control of the activity of NMDA
receptors on the spines. It is possible that during neurodevel-
opment in prenatal and early life, genetic and environmental
stress factors cause atypical formation of separated local
(small) neuron groups.

These partially isolated local neuron groups may work in
a random manner as closed-loop synchronized units with
increased excitability and produce local paroxysms. Hu-
mans’ brain circuitry is not mature until after age twenty.
When the adolescent brain is swamped by stress, sex, and
growth hormones, and with concomitant increases in the activity of the hypothalamic–pituitary–adrenal system, atypical separated local (small) neuron groups are also activated. These local neuron groups can remain partially isolated throughout life because they are separated from the perspective of information. This may explain why schizophrenia is such a complex and lifelong brain disorder.

However, most intra- and interneuronal signal processes are subject to redox control and modulation in a direct or indirect manner, as was represented in this paper. It has been accepted that glutamate receptors are the primary molecular structure controlling synaptic plasticity and memory function in the brain. Several biochemical steps of NMDA receptor activation are redox-regulated/linked processes controlled by reactive species (free radicals) and their derivatives. In addition, volume transmission of dopamine can capture free radicals and chelating zinc (and other) ions in the synaptic cleft and may have an important role in retrograde signaling via metabotropic GluR mechanisms in a G-protein-mediated manner.

Moreover, dopamine can reversibly regulate (net inhibitory effect) mitochondrial motility. Thus, excess dopamine can produce dysfunctions of mitochondrial distribution (i.e., perturbation of mitochondrial fusion and fission processes) and metabolic functions as has also been suggested for schizophrenia. Because neuronal activity and energy metabolism are direct coupled mechanisms, and regions high in neuronal activity - particularly the glutamatergic ones - have high levels of mitochondrial activity, excess dopamine can perturb neuronal activity via the expression of mitochondrial networks and glutamatergic NMDA receptors.

Additionally, although dopamine oquinone can rapidly recover to dopamine, excess dopamine production - in the context of insufficient antioxidants - results in formation of neurotoxic osemiquinone free radicals from oquinones. These free radicals also cause malfunctions of synaptic processes.

Phosphorylation of NMDAR subunits by protein kinases is also free radical associated. In addition, redox-mediated activation of NMDA receptors induces a series of further redox-associated free radical signaling processes, such as NADPH oxidase activity, neuronal nitric oxide synthase (nNOS) activity, mitochondrial enzyme activity, induction of the arachidonic acid cascade, phospholipase A, and prostaglandin H (PGH) synthase. Furthermore, research has shown that serotonin can modulate dopaminergic functions.

Since dopamine can exert a net inhibitory effect on mitochondrial movement (mitochondria are key determinants of the excitability and viability of neurons and act as metabolic hubs) and induce overproduction of H2O2 and superoxides via monoamine oxidase, which inhibits mitochondrial respiration, this restriction of mitochondrial movement (fusion, fission, redistribution) and respiration can constrain the ongoing neuronal information processes and cause closed-loop synchronized activity in local neuron groups that can produce local paroxysms. In addition, because the dopamine primordially performs volume transmission (and most dopamine receptors are positioned at extrasynaptic sites), excess dopamine production in local deafened neuron areas can have an especially important regulatory effect on the release of various neurotransmitters (and their receptors) and on classic synaptic communication.

Because the majority of dopamine (monoaminergic) varicosities create nonsynaptic contact that enables the release of transmitters directly into the extrasynaptic space, catecholamines and serotonin have free radical scavengers, and the effect of nonsynaptic volume neurotransmission (paracrine or diffusion neurotransmission) may be not as exact as classical communication by the synaptic mechanism, it is also very important to approach complex causal mechanisms of schizophrenia from a nonsynaptic and redox point of view.

CONFLICT OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content.

ACKNOWLEDGEMENT

Bókkon I. gratefully acknowledges support of this work by the BioLabor (Hungary), www.biolabor.org; Bókkon’s URL: http://bokkon-brain-imagery.5mp.eu

REFERENCES

[1] Cannon, T.D.; van Erp, T.G.; Bearden, C.E.; Loewy, R.; Thompson, P; Toga, A.W.; Huttonen, M.O.; Keshavan, M.S.; Seidman, L.J.; Tsuang, M.T. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr. Bull. 2003, 29, 653-669.
[2] Green, M.F. Schizophrenia Revealed: From Neurons to Social Interactions. W. W. Norton & Company, Inc.: New York, 2001.
[3] Harrison, P. Dopamine and schizophrenia-proof at last? Lancet, 2000, 356, 956-959.
[4] Beneyto, M.; Kristiansen, L.V.; Oni-Orisan, A.; McCullumsmith, R.E.; Meador-Woodruff, J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology, 2007, 32, 1888-1902.
[5] Meador-Woodruff, J.H.; Healy, D.J. Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev., 2000, 31, 288-294.
[6] Csernansky, J.G.; King, R.J.; Faustman, W.O.; Moses, J.A.Jr.; Friedman, J.I.; Adler, D.N.; Davis, K.L. The role of norepinephrine and serotonin-dopamine interaction: an overview. Prog. Brain Res., 2007, 156, 501-507.
[7] Abi-Dargham, A.; Laruelle, M.; Aghajanian, G.K.; Charnay, D.; Krystal, J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatry Clin. Neurosci., 1997, 9, 1-17.
[8] Friedman, J.I.; Adler, D.N.; Davis, K.L. The role of norepinephrine in the physiopathology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer’s disease. Biol. Psychiatry, 1999, 46, 1243-1252.
[9] Esposito, E.; Di Matteo, V.; Di Giovanni, G. Serotonin-dopamine interaction: an overview. Prog. Brain Res., 2008, 172, 3-6.
[10] Ennis, C.; Kemp, J.D.; Cox, B. Characterisation of inhibitory 5-hydroxtryptamine receptors that -1520.modulate dopamine release in the striatum. J. Neurochem., 1981, 36, 1515.
[11] Westfall, T.C.; Titternary, V. Inhibition of the electrically induced release of [3H] dopamine by serotonin from superfused rat striatal slices. Neurosci. Lett., 1982, 28, 205-209.
[12] Benloucif, S.; Galloway, M.P. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur. J. Pharmacol., 1991, 200, 1-8.
[13] De Deurwaerdere, P.; Chironnel, M.; Bonhomme, N.; Lucas, G.; Cheramy, A.X.; Spampinato, U. Serotonin stimulation of 5-HT4
receptors indirectly enhances in vivo dopamine release in the rat striatum. J. Neurochem., 1997, 68, 195-203.

[14] Winter, J.C. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl.), 2009, 203, 251-263.

[15] Coyle, J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem. Pharmacol., 2004, 68, 1507-1514.

[16] Terry, A.V.Jr. Role of the central cholinergic system in the therapeutics of schizophrenia. Curr. Neuropharmacol., 2008, 6, 286-292.

[17] Ben-Shachar, D.; Laitinenféld, D. Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol., 2004, 59, 273-296.

[18] Do, K.Q.; Trabesinger, A.H.; Kirsten-krüger, M.; Lauer, C.J.; Dydak, U.; Hell, D.; Holsboer, F.; Boesiger, P.; Cuénot, M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci., 2000, 12, 3721-3728.

[19] Gynis, R.; Kraftis, R.; Sandell, J.; Bovet, P.; Chappuis, C.; Conus, P.; Deppen, P.; Freig, M.; Ruz, V.; Steullet, P.; Tosic, M.; Werge, T.; Cuénot, M.; Do, K.Q. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. USA, 2007, 104, 16621-16626.

[20] Steullet, P.; Nejac, H.C.; Cuénot, M.; Do, K.Q. Synaptic plasticity impairment and hyperfunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience, 2006, 137, 807-819.

[21] Yarlagadda, A. Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions. Med. Hypotheses, 2002, 58, 182-186.

[22] Ramon y Cajal, S. Histologie du système nerveux de l’homme et des vertébrés. Paris, Maloin, 1911.

[23] Paton, W.D.; Vizi, E.S. The inhibitory action of noradrenaline and adrenaline on acetylcholine output by guinea-pig ileum longitudinal muscle strip. Br. J. Pharmacol., 1969, 35, 10-28.

[24] Knoll, J.; Vizi, E.S. Effect of frequency of stimulation on the inhibition by noradrenaline of the acetylcholine output from parasympathetic nerve terminals. Br. J. Pharmacol., 1971, 42, 263-272.

[25] Vizi, E.S. Prenaptic modulation of neurochemical transmission. Prog. Neurobiol., 1979, 12, 181-290.

[26] Vizi, E.S. Modulation of cortical release of acetylcholine by noradrenaline released from nerves arising from the rat locus coeruleus. Neuroscience, 1980, 5, 2139-2144.

[27] Dismukes, K. New look at the amnergic nervous system. Nature, 1977, 269, 557-558.

[28] Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem., 1992, 59, 1609-1623.

[29] Dröge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82, 47-95.

[30] Kovacic, P.; Jacintho, J.D. Mechanisms of carcinogenesis: Focus on oxidative stress and electron transfer. Curr. Med. Chem., 2001, 8, 773-796.

[31] Ridnour, L.A.; Thomas, D.D.; Mancardi, D.; Espey, M.G.; Miranda, K.M.; Paolocci, N.; Feilisch, M.; Fukuto, J.; Wink, D.A. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species: putting perspective on stressful biological situations. Biochem. 2004, 385, 1-10.

[32] Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological situations. Biochem. Pharmacol., 2005, 74, 837-846.

[33] Skulachev, V.P. Mitochondrial filaments and clusters as intracellular power-transmitting cables. Trends Biochem. Sci., 2001, 26, 23-29.
Andorn, A.C.; Pappolla, M.A. Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain. *Acta Neurobiol. Exp.*, 2006, 66-74.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.

Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, S.; Smythies, J. Redox mechanisms at the glutamate synapse and their significance: a review. *Eur. J. Pharmacol.*, 1999, 329, 1-7.
the dendritic spines of medium spiny neurons in rat striatum. *Neuroscience, 1998*, 83, 749-761.

[105] Knapp, I.T.; Klann, E. Role of reactive oxygen species in hippocampal long-term potentiation: contributory or inhibitory? *J. Neurosci. Res., 2002*, 70, 1-7.

[106] Rhee, S.G. H2O2, a necessary evil for cell signaling. *Science, 2006*, 312, 1882-1883.

[107] Veal, E.A.; Day, A.M.; Morgan, B.A. Hydrogen peroxide sensing and signaling. *Mol. Cell, 2007*, 26, 1-14.

[108] Avshalumov, M.V.; Chen, B.T.; Marshall, S.P.; Peha, D.M.; Rice, M.E. Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible messenger, H2O2. *J. Neurosci., 2003*, 23, 2744-2750.

[109] Chen, B.S.; Roche, K.W. Regulation of NMDA receptors by phosphorylation. *Neuropsychopharmacology, 2007*, 32, 362-368.

[110] Wang, Y.T.; Salter, M.W. Regulation of NMDA receptors by tyrosine kinases and phosphatases. *Nature, 1994*, 369, 233-235.

[111] Chiarugi, P. PTPs versus PTKs: the redox side of the coin. *Free Radic. Res., 2005*, 39, 353-364.

[112] Chiarugi, P.; Buricchi, F. Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslational modifications. *Antioxid. Redox Signal., 2007*, 9, 1-24.

[113] Wu, R.F.; Terada, I.S. Oxidative modification of protein tyrosine phosphatases. *Sci. STKE, 2006*, 332, p.12.

[114] Li, B.; Devidze, N.; Barenholz, D.; Prostaglandins, E.; Barengolts, D.; Prostak, N.; Sphicas, E.; Schoepp, D.D. Unveiling the Functions of Presynaptic Metabotropic Glutamate Receptors in the Central Nervous System. *J. Pharmacol. Exp. Ther., 2001*, 299, 12-20.

[115] Feenstra, M.G.P.; Botterblom, M.H.A.; van Uum, J.F.M. Local activation of metabotropic glutamate receptors inhibits the handling-induced increased release of dopamine in the nucleus accumbens but not that of dopamine or noradrenaline in the prefrontal cortex: Comparison with inhibition of ionotropic receptors. *J. Neurochem., 1998*, 70, 1104-1113.

[116] Hu, G.; Duffy, P.; Swanson, C.; Ghasemzadeh, M.B.; Kalivas, P.W. The regulation of dopamine transmission by metabotropic glutamate receptors. *J. Pharmacol. Exp. Ther., 1999*, 289, 412-416.

[117] Verma, A.; Moghaddam, B. Regulation of striatal dopamine release by metabotropic glutamate receptors. *Synapse, 1998*, 28, 220-226.

[118] Spillson, A.B.; Russell, J.W. Metabotropic glutamate receptor regulation of neuronal cell death. *Exp. Neuro., 2003*, 184 (Suppl 1), S97-S105.

[119] Ishii, T.; Moriyoshi, K.; Sugihara, H.; Sakurada, K.; Kadotani, H.; Yokoi, M.; Akazawa, C.; Shigemoto, R.; Mizuno, N.; Masu, M.; Nakanishi, S. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. *J. Biol. Chem., 1993*, 268, 2836-2843.

[120] Kutsuwada, T.; Kashikawa, N.; Mori, H.; Sakimura, K.; Kushiya, E.; Araki, K.; Meguro, H.; Masaki, H.; Kumanishi, T.; Arakawa, M.; Mishina, M. Molecular diversity of the NMDA receptor channel. *Nature, 1992*, 358, 36-41.

[121] Assaf, S.Y.; Chung, S.H. Release of endogenous Zn²⁺ from brain tissue during activity. *Nature, 1984*, 308, 734-736.

[122] Howell, G.A.; Welch, M.G.; Frederickson, C.J. Stimulation-induced uptake and release of zinc in hippocampal slices. *Nature, 1984*, 308, 736-738.

[123] Iizumi, Y.; Auberson, Y.P.; Zorumski, C.F. Zinc modulates bidirectional hippocampal plasticity by effects on NMDA receptors. *J. Neurosci., 2006*, 26, 7181-7188.

[124] Pfifl, C.; Wolf, A.; Rebernik, P.; Reither, H.; Berger, M.L. Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner. *Neuropsychopharmacology, 2009*, 36, 531-540.

[125] Iizumi, Y.; Moriya, K.; Mellor, J.; Tong, G.; Nicoll, R. The actions of synthetically released zinc at hippocampal mossy fiber synapses. *Neuron, 2000*, 26, 187-196.

[126] Szyf, M. Towards a pharmacology of DNA methylation. *Trends Pharmacol. Sci., 2001*, 22, 350-354.

[127] Browne, M.J.; Turnbull, J.F.; McKay, E.L.; Adams, R.L.; Burdon, R.H. The sequence specificity of a mammalian DNA methylase. *Nucleic Acids Res., 1977*, 4, 1039-1045.

[128] Costa, E.; Chen, Y.; Dong, E.; Grayson, D.R.; Guidotti, A.; Veldic, M. Reelin downregulation as a prospective treatment target for GABAergic dysfunction in schizophrenia. In: Reelin Glycoprotein: Structure, Biology and Roles in Health and Disease; S. Hossein Fatemi, S; Ed: Springer: New York, 2008, pp. 341-63.

[129] Dong, E.; Agis-Balboa, R.C.; Simonini, M.V.; Grayson, D.R.; Costa, E.; Guidotti, A. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. *Proc. Natl. Acad. Sci. USA, 2005*, 102, 12578-12583.

[130] Guidotti, A.; Dong, E.; Kundakovic, M.; Satta, R.; Grayson, D.R.; Costa, E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. *Trends Pharmacol. Sci., 2009*, 30, 55-60.

[131] Hitchcock, M.J.; Domann, F.E. An epigenetic perspective on the free radical theory of development. *Free Radic. Biol. Med., 2007*, 43, 1023-1036.

[132] Schafer, F.Q.; Buettner, G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic. Biol. Med., 2001*, 30, 1191-1212.

[133] Gardner, D.M.; Baldessarini, R.J.; Warach, M. Modern antipsychotic drugs: a critical overview. *CMAJ, 2005*, 172, 1703-1711.

[134] Rosenheck, R.; Leslie, D.; Kreek, M.; Meevoy, J.; Swartz, M.; Perkins, D.; Strop, S.; Hisao, J.K.; Lieberman, J. Barriers to employment for people with schizophrenia. *Am. J. Psychiatry, 2006*, 163, 411-417.

[135] Heresco-Levy, U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. *Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003*, 27, 1113-1123.

[136] Paz, R.D.; Tardito, S.; Atzori, M.; Tseng, K.Y. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. *Eur. Neuropsychopharmacol., 2008*, 18, 773-786.

[137] Llorente, M.D.; Urrutia, V. Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. *Clinical Diabetes, 2006*, 24, 18-24.

[138] Margolese, H.C.; Ferreri, F. Management of conventional antipsychotic-induced tardive dyskinesia. *J. Psychiatry Neurosci., 2007*, 32, 72.

[139] Uçok, A.; Gaebel, W. Side effects of atypical antipsychotics: a brief overview. *World Psychiatry, 2008*, 7, 58-62.

[140] Ben-Shachar, D.; Livne, E.; Spanier, I.; Zuk, R.; Youdim, M.B. Iron modulates neuroleptic-induced effects related to the dopaminergic system. *Isr. J. Med. Sci., 1993*, 29, 587-592.

[141] Ben-Shachar, D.; Livne, E.; Spanier, I.; Leenders, K.L.; Youdim, M.B. Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. *J. Neurochem., 1994*, 62, 1112-1118.

[142] Berger, I.; Segal, I.; Shmueli, D.; Saada, A. The effect of antiepileptic drugs on mitochondrial activity: a pilot study. *J. Child Neurol., 2010*, 25, 541-545.

[143] Benavides, J.; Martin, A.; Ugarte, M.; Valdivieso, F. Inhibition by valproic acid of pyruvate uptake by brain mitochondria. *Biochem. Pharmacol., 1982*, 31, 1633-1636.

[144] Casademont, J.; Garrabou, G.; Miró, O.; López, S.; Pons, A.; Bernardo, M.; Cardellach, F. Neuronal treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. *J. Clin. Psychopharmacol., 2007*, 27, 284-288.
[148] Duan, W.; Ladenheim, B.; Cutler, R.G.; Kruman, I.I.; Cadet, J.L.; Mattson, M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. *J. Neurochem.*, **2002**, *80*, 101-110.

[149] Sener, U.; Zorlu, Y.; Karaguzel, O.; Ozdamar, O.; Coker, I.; Topbas, M. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. *Seizure*, **2006**, *15*, 79-85.

[150] Austin, R.C.; Sood, S.K.; Dorward, A.M.; Singh, G.; Shaughnessy, S.G.; Pamidi, S.; Outinen, P.A.; Weitz, J.I. Homocysteine-dependent alterations in mitochondrial gene expression, function, and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage. *J. Biol. Chem.*, **1998**, *273*, 30808-30817.

[151] Burke, W. The neural basis of Charles Bonnet hallucinations: a hypothesis. *J. Neurol. Neurosurg. Psychiatry*, **2002**, *73*, 535-541.